- Metabolon Launches Specific Panels of Bile Acids and Short Chain Fatty Acids to Advance Knowledge of the Gut Microbiome and Metabolome in Health and Disease
Targeted metabolomics panels provide absolute quantification of important bioactive intermediates of the microbiome and gastrointestinal gut health
MORRISVILLE, N.C., April 4, 2023 /PRNewswire/ -- Metabolon, Inc., a world leader in providing metabolomics solutions that advance a wide variety of research, diagnostic, therapeutic development and precision medicine applications, has announced today the launch of its specific panels of bile acids and short chain fatty acids, which measure metabolites of biological importance of microbial origin to identify biomarkers for the prediction and early detection of diseases, such as oncology, neurology, liver, diabetes and gastrointestinal and intestinal health.
Taken together, this new set of panels targets dozens of metabolites of microbial origin through multiple pathways, including bile acid metabolism, sulfur metabolism, nitrogen metabolism, and B vitamin metabolism to advance preclinical and clinical research efforts:
"Metabolomics is a powerful tool that provides insight into a disease phenotype, crucial for effective disease prevention, monitoring and treatment," said Dr. Rohan (Ro) Hastie, President and CEO of Metabolon . "Metabolon is committed to advancing the scientific understanding of the human microbiome and its impact on human health. Our targeted panels of bile acids and short-chain fatty acids address an important need for today's cutting-edge researchers and will help unlock new insights into the complex interplay between diet, gut health, and disease, paving the way for the development of more personalized and targeted therapies."
"Our world-class ISO 9001 laboratory has developed two quantitative panels to assist researchers working in oncology, liver, diabetes and gut health. These panels will provide additional metabolite coverage beyond our Global Discovery Platform to assist our clients to gain rapid insight into the role of specific microbiome-related pathways influencing human biology to ultimately move closer to understanding and combating many important diseases," said Rangaprasad (Ranga) Sarangarajan, Ph. D., chief scientific officer of Metabolon.
To learn more about how Metabolon deciphers thousands of discrete chemical signals from genetic and non-genetic factors to discover biomarkers and reveal biological pathways, visit https://www.metabolon.com/.
About Metabolon Metabolon, Inc. is the world leader in metabolomics, with a mission to provide biochemical data and insights that amplify and accelerate the impact of life science research. Through 20 years, 10,000+ projects, 3,000+ publications, and ISO 9001:2015 and CLIA certifications, Metabolon has developed industry-leading scientific, technological, and bioinformatics techniques. The Metabolon Global Discovery Panel is powered by the world's largest proprietary metabolomic reference library. Metabolon's industry-leading data and translational science expertise help customers and partners address some of the most challenging and pressing questions in the life sciences, accelerating research and improving development success. The company offers scalable and customizable lipidomics and metabolomics solutions that meet customer needs from discovery to clinical trials to product lifecycle management. For more information visit www.metabolon.com and follow us on LinkedIn and Twitter.
About MetabolomicsMetabolomics, the large-scale study of all the small molecules in a biological system, is the only omics technology that provides a complete functional readout of the current state of a biological system. Metabolomics helps researchers see beyond the genetic variation of individuals, capturing the combined impact of genetic and external factors such as the effect of drugs, diet, lifestyle, and the microbiome on human health. By measuring thousands of discrete chemical signals that form biologic pathways in the body, metabolomics can reveal important biomarkers that can better understand a drug's mechanism of action, pharmacodynamics, and safety profile, as well as individual responses to treatment.
Logo - https://mma.prnewswire.com/media/1671125...
View original content: https://www.prnewswire.com/news-releases/metabolon-lanza-paneles-especificos-de-acidos-biliares-y-acidos-grasos-de-cadena-corta-301789476.html
